148 related articles for article (PubMed ID: 11104621)
1. Long-term follow-up of the Stockholm screening study on ovarian cancer.
Einhorn N; Bast R; Knapp R; Nilsson B; Zurawski V; Sjövall K
Gynecol Oncol; 2000 Dec; 79(3):466-70. PubMed ID: 11104621
[TBL] [Abstract][Full Text] [Related]
2. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
3. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
[TBL] [Abstract][Full Text] [Related]
4. Relapse and survival in early-stage ovarian cancer.
Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
[TBL] [Abstract][Full Text] [Related]
5. Serum CA-125 screening for ovarian cancer in patients with dermatomyositis.
Whitmore SE; Anhalt GJ; Provost TT; Zacur HA; Hamper UM; Helzlsouer KJ; Rosenshein NB
Gynecol Oncol; 1997 May; 65(2):241-4. PubMed ID: 9159332
[TBL] [Abstract][Full Text] [Related]
6. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
[TBL] [Abstract][Full Text] [Related]
7. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women.
Skates SJ; Menon U; MacDonald N; Rosenthal AN; Oram DH; Knapp RC; Jacobs IJ
J Clin Oncol; 2003 May; 21(10 Suppl):206s-210s. PubMed ID: 12743136
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up study of a population-based 1996-1998 mass screening programme for lung cancer using mobile low-dose spiral computed tomography.
Sone S; Nakayama T; Honda T; Tsushima K; Li F; Haniuda M; Takahashi Y; Suzuki T; Yamanda T; Kondo R; Hanaoka T; Takayama F; Kubo K; Fushimi H
Lung Cancer; 2007 Dec; 58(3):329-41. PubMed ID: 17675180
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer.
Einhorn N; Sjövall K; Knapp RC; Hall P; Scully RE; Bast RC; Zurawski VR
Obstet Gynecol; 1992 Jul; 80(1):14-8. PubMed ID: 1603484
[TBL] [Abstract][Full Text] [Related]
10. Survival of ovarian cancer patients in Denmark: excess mortality risk analysis of five-year relative survival in the period 1978-2002.
Hannibal CG; Cortes R; Engholm G; Kjaer SK
Acta Obstet Gynecol Scand; 2008; 87(12):1353-60. PubMed ID: 18951210
[TBL] [Abstract][Full Text] [Related]
11. Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study.
Vernooij F; Heintz AP; Witteveen PO; van der Heiden-van der Loo M; Coebergh JW; van der Graaf Y
J Natl Cancer Inst; 2008 Mar; 100(6):399-406. PubMed ID: 18334710
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study.
Suh-Burgmann E
Gynecol Oncol; 2006 Dec; 103(3):841-7. PubMed ID: 16793124
[TBL] [Abstract][Full Text] [Related]
13. Women's awareness of ovarian cancer risks and symptoms.
Lockwood-Rayermann S; Donovan HS; Rambo D; Kuo CW
Am J Nurs; 2009 Sep; 109(9):36-45; quiz 46. PubMed ID: 19704232
[TBL] [Abstract][Full Text] [Related]
14. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
15. A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not?
Carney ME; Lancaster JM; Ford C; Tsodikov A; Wiggins CL
Gynecol Oncol; 2002 Jan; 84(1):36-42. PubMed ID: 11748973
[TBL] [Abstract][Full Text] [Related]
16. Ovarian cancer screening: a look at the evidence.
Fields MM; Chevlen E
Clin J Oncol Nurs; 2006 Feb; 10(1):77-81. PubMed ID: 16482731
[TBL] [Abstract][Full Text] [Related]
17. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
18. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
19. Non-genital tract metastases to the ovaries presented as ovarian tumors in Sweden 1990-2003: occurrence, origin and survival compared to ovarian cancer.
Skírnisdóttir I; Garmo H; Holmberg L
Gynecol Oncol; 2007 Apr; 105(1):166-71. PubMed ID: 17184826
[TBL] [Abstract][Full Text] [Related]
20. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
Fotopoulou C; duBois A; Karavas AN; Trappe R; Aminossadati B; Schmalfeldt B; Pfisterer J; Sehouli J;
J Clin Oncol; 2008 Jun; 26(16):2683-9. PubMed ID: 18509180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
